Clinical trial
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Study timeline
Study start (actual)2019-11-07Date precision: day
Registry last updated2025-11-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Urothelial Cancerunresolved
Ovarian Cancerunresolved
Non-small Cell Lung Cancerunresolved
Head and Neck Cancerunresolved
Triple Negative Breast Cancerunresolved
Gastric/Upper Gastrointestinal Cancerunresolved
Interventions
BT5528DRUG
NivolumabDRUG · verified · RxNorm: nivolumab
Sponsors & collaborators
BicycleTx Limitedlead sponsor
Mapped research locations
MadridSpain3BarcelonaSpain2BrusselsBelgium2New YorkNew York, United States1HoustonTexas, United States1PhiladelphiaPennsylvania, United States1NashvilleTennessee, United States1SeoulSouth Korea1DenverColorado, United States1Oklahoma CityOklahoma, United States1DetroitMichigan, United States1Las VegasNevada, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04180371 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.